Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MultiCenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of ATX-101 (Sodium Deoxycholate Injection) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area

Next Previous
Trial Profile

MultiCenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of ATX-101 (Sodium Deoxycholate Injection) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 17 Oct 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Deoxycholic acid (Primary)
  • Indications Subcutaneous fat disorders
  • Focus Registrational; Therapeutic Use
  • Acronyms REFINE-2
  • Sponsors Kythera Biopharmaceuticals

    • Most Recent Events

    • 11 Oct 2018 According to an Allergan media release, data from this study will be presented at the 2018 American Society For Dermatologic Surgery Meeting.
    • 15 Jul 2016 Results published in the Journal of the American Academy of Dermatology (2016).
    • 01 Jul 2016 According to an Allergan media release, the company has received positive opinion from the Swedish Medical Products Agency (MPA) for deoxycholic acid (BELKYRA) through European decentralised procedure for the treatment of subdermal fullness.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top